SpyGlass Pharma, Inc. 8-K

What Happened

• SpyGlass Pharma, Inc. filed an 8-K on Feb. 13, 2026 reporting that its Compensation Committee approved performance cash bonuses for the company's Named Executive Officers on Feb. 12, 2026.
• The approval follows the company's Form S-1 (filed Jan. 16, 2026, File No. 333-292779), which had disclosed that bonus amounts for fiscal year 2025 had not yet been determined and would be disclosed once set. The bonuses will be paid shortly after approval.

Key Details

• Form S-1 originally noted bonuses for the principal executive officer and up to two other most highly compensated executives (the “Named Executive Officers”) were pending determination.
• Compensation Committee approval date: February 12, 2026. 8-K filing date: February 13, 2026.
• The 8-K confirms approval and impending payment but does not state specific dollar amounts for the bonuses.

Why It Matters

• For investors, approved executive performance bonuses affect cash outflows and executive compensation disclosure — amounts previously left pending in the S-1 will now be finalized and should be reported as required.
• Knowing these bonuses can help investors assess management incentives and potential near-term cash impact, especially around corporate filings (S-1) and any related liquidity assessments.